ELISMA, UAB - financials and debts

Company age: 20 y. 5 mo.

Update

vaistinė ELISMA - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 1,193,551 1,219,708 1,446,324 1,562,020 1,500,654 1,536,793 1,173,536 968,470
Profit before tax 28,524 7,749 8,804 4,573 15,470 -24,031 8,807 4,814
Net profit 25,714 6,587 7,483 3,887 13,299 -24,031 8,411 4,583
Equity 74,580 57,390 47,621 39,655 64,098 39,884 48,513 53,134
Liabilities 293,226 176,671 303,070 365,112 307,835 276,093 182,212 147,203
Non-current assets 35,578 25,755 35,639 86,912 71,844 74,161 51,050 49,100
Current assets 332,228 208,306 315,052 328,686 287,190 265,114 193,105 166,251
Total assets 367,806 234,061 350,691 415,598 359,034 339,275 244,155 215,351
Taxes paid
STI taxes - - - - - 78,548 66,817 46,343
Social insurance contributions - - - - - 57,362 46,105 33,013
Financial indicators
Revenue change y/y -5.3% +2.2% +18.6% +8.0% -3.9% +2.4% -23.6% -17.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 7.0% 2.8% 2.1% 0.9% 3.7% -7.1% 3.4% 2.1%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 34.5% 11.5% 15.7% 9.8% 20.7% -60.3% 17.3% 8.6%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.2% 0.5% 0.5% 0.2% 0.9% -1.6% 0.7% 0.5%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 2.4% 0.6% 0.6% 0.3% 1.0% -1.6% 0.8% 0.5%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 3.9 3.1 6.4 9.2 4.8 6.9 3.8 2.8
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 91,812 93,824 111,256 123,317 136,423 139,708 132,854 136,726

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

vaistinė ELISMA - Social security debts

From To Debt, €
2026-09-05 2026-09-07 2.30
2026-08-26 2026-09-02 2.30
2026-08-23 2026-08-23 2.30
2026-08-19 2026-08-19 2.30
2026-07-27 2026-08-06 2.30
2026-07-26 2026-07-26 2.00
2026-07-23 2026-07-25 2.30
2026-07-21 2026-07-22 2.00
2026-07-19 2026-07-20 125.83
2026-07-16 2026-07-17 125.83
2026-05-17 2026-05-20 179.19
2026-04-20 2026-04-22 3.73

vaistinė ELISMA - VMI tax arrears

From To Overdue, €
2026-03-02 2026-03-21 0.09
2026-02-21 2026-02-21 0.54
2026-01-29 2026-02-16 0.54

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
ELISMA, UAB (code 300562704) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of EUR 968.5K, down 17.5% year on year and 37.0% over two years. Despite the weaker turnover, profitability remained positive: net profit was EUR 4.6K, compared with EUR 8.4K in 2024 and a net loss of EUR 24.0K in 2023. The 2025 profit margin was 0.5%, following 0.7% in 2024 and -1.6% in 2023. Balance sheet indicators also narrowed during the period, with total assets decreasing from EUR 339.3K in 2023 to EUR 215.4K in 2025. Equity rose gradually to EUR 53.1K, while liabilities declined to EUR 147.2K. The latest equity ratio was 24.7% and debt-to-equity stood at 2.77. Asset turnover remained strong at 4.50x, and revenue per employee was EUR 138.4K, with profit per employee of EUR 655.